

2015.1A

Question 3 Amiodarone Subject: Pharm LOA: 1	What anti-arrhythmic class does amiodarone belong to? What are the effects of amiodarone on the heart?	<b>Class 3:</b> also class I,II,IV effects  <b>Increases Action potential duration (APD) due to blockade</b> of rapid component of delayed K <sup>+</sup> current (I <sub>Kr</sub> ). Chronic use also blocks slow K <sup>+</sup> rectifier. <b>Prolongs QT</b> (due to above effect) Blocks inactivated Na <sup>+</sup> channels. Weak adrenergic and Ca <sup>++</sup> channel blocker Atrial Fibrillation/ Ventricular tachycardia/Ventricular fibrillation/ Supraventricular (re-entrant/ accessory)	Bold to pass  Bold to pass
	What other arrhythmias is amiodarone used for?	Torsades de pointes (rare < 1%), Bradycardia, Heart block	2 to pass
	What arrhythmias may amiodarone cause?		1 to pass

2015.1B

Question 3 Metaraminol (chp 9)  Subject: Pharm LOA: 1	What is the mechanism of action of Metaraminol?	Direct <b>alpha 1 receptor agonist</b> – some indirect effect through increased noradrenaline.	Bold
	What are its effects on the cardiovascular system?	<b>Vaso and arterio – constriction</b> in vascular beds. Arterioconstriction → <b>↑BP</b> Direct cardiac effects less important HR slows due to vagal feedback CO unchanged or slight decrease as ↑VR and hence SV	Bold
	What role do sympathomimetics have in management of shock?	Temporising only While other treatment instituted – fluids, etc Efficacy not proven Useful in 'failure' sympathetic NS (eg/ spinal injury or anaesthesia)	Understanding of temporary only

2015.1C

Question 4 Glyceryl Trinitrate Subject: Pharm LOA: 1	What is the mechanism of action of GTN	Nitrite -> <b>NO</b> -> ↑ cGMP -> <b>Smooth m relaxation</b> . Prostaglandins may be involved	<b>Bold</b>
	What are its clinical effects?	1. Beneficial effects- <b>venodilation</b> , reduced venous return, decr ventricular pre-load, reduced LVEDV, reduced LV wall tension, <b>reduced myocardial oxygen consumption</b> . Vasodilation of epicardial coronary arteries, increased coronary collateral flow. <b>Decrease systemic BP</b> 2. Adverse effects - hypotension, tachycardia, headache	<b>2 of 3 Bold</b>  <b>2 adverse effects</b>
	What are the indications for GTN use in the ED?	<b>Angina</b> , acute coronary syndrome, hypertensive urgencies/emergencies, APO, aortic dissection (with beta-blockade)	<b>Bold plus two others</b>

2014.2A

Question 2 Subject: Pharm Metoprolol / Beta blockers (Ch 10) LOA: 1	1. Describe the pharmacokinetics of metoprolol <b>Prompt</b> what is its bioavailability and why?	Oral or IV, Vd – large, T ½ 3 – 4 hrs, Metabolised in liver Bioavailability 50% due to 1 <sup>st</sup> pass effect.	<b>Oral &amp; IV &amp; 1<sup>st</sup> pass</b> Or <b>3/5</b>
	2. How does metoprolol differ from propranolol in its action at beta receptors?	Beta 1 – full agonist Beta 2 - 50 – 100 fold less potent	<b>B1 Selective</b>
	3. How do BB control hypertension?	Negative <b>inotropic and chronotropic</b> effects Slow a-v node conduction Antagonises release of renin/not fully understood.	<b>Negative inotropic &amp; chronotropic effect</b>

## 2014.2B

<p><b>Question 3</b> Frusemide (pp 258-260)</p> <p><b>Subject:</b> Pharm LOA: 1</p>	<p>1. How does frusemide exert its action?</p>	<p><b>Selectively inhibits Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> transporter in thick ascending limb of loop of Henle thus preventing resorption of Na<sup>+</sup> &amp; Cl<sup>-</sup></b></p> <p>Abolishes counter-current concentrating mechanism leading to dilute urine.</p> <p>Increased prostaglandin synthesis -&gt; inhibition of salt transport in thick ascending limb -&gt; increased renal blood flow, decreased pulmonary congestion, decreased LV filling pressures</p>	<p>Bold to pass</p>
	<p>2. What are the pharmacokinetic properties of frusemide?</p>	<ul style="list-style-type: none"> <li>• Rapid absorption after oral admin</li> <li>• Oral bioavailability 50% (range 10 –100%)</li> <li>• Highly protein-bound (&gt;95%)</li> <li>• 50% conjugated in kidney &amp; 50% excreted in urine unchanged (tubular secretion)</li> <li>• Elimination t<sub>1/2</sub> 1.5 – 2 hours</li> <li>• Peak effect 30 minutes IV / 1 hour oral</li> </ul>	<p>List 3</p>
	<p>3. What are the potential adverse effects of frusemide?</p> <p>PROMPT: What are the electrolyte disturbances?</p>	<ul style="list-style-type: none"> <li>• Electrolyte disturbances               <ul style="list-style-type: none"> <li>• <b>hypokalaemia,</b></li> <li>• hyponatraemia,</li> <li>• hypomagnesaemia,</li> <li>• hyperuricaemia</li> </ul> </li> <li>• Postural <b>hypotension</b> &amp; dizziness</li> <li>• Metabolic Alkalosis</li> <li>• Allergy - rash, eosinophilia, interstitial nephritis</li> <li>• Increased LDL &amp; triglycerides, decreased HDL</li> <li>• Hyperglycaemia</li> <li>• Ototoxicity (high dose IV)</li> </ul>	<p>Bold plus 2</p>

## 2014.1A

<p><b>Question 4</b> Compound Sodium Lactate (MIMs &amp; product information) Constitution, Indications, Adverse effects. Comparison to other crystalloids and colloids</p> <p><b>Subject:</b> Pharm LOA: 1</p>	<p>(a) How does Hartmann's solution differ from normal saline?</p>	<p>Addition of <b>Sodium Lactate, Potassium Chloride, Calcium Chloride</b> (+pH adjustment) Na 131, K 5, Cl 112, Ca 2, Lactate/Bicarb 28 mmol Compare Normal Saline Na 150 Cl 150)</p>	<p>Bold</p>
	<p>(b) What are the potential advantages of Hartmann's solution in resuscitation?</p>	<p>Closer to physiologic – potassium, calcium <b>Less Hyperchloraemia</b> <b>Effective bicarbonate – some (slow) good effect on acidosis</b> (proof of superiority lacking)</p>	<p>Bold</p>
	<p>(c) What are the potential complications of IV fluid therapy?</p>	<p>overload/under resuscitation, hypothermia, extravasation, acidosis, electrolyte abnormalities, osmo changes, air embolism, infection, cerebral oedema, haemodilution</p>	<p>Bonus</p>

2014.1A

<p><b>Question 4</b> ACE inhibitors <b>Subject:</b> Pharm</p>	<p>What is the mechanism of action of captopril?</p>	<p><b>Angiotensin converting enzyme (kininase II) inhibitor:</b> inhibits hydrolysis of A1 to A2. Hence, <b>inhibits A2</b> effects (potent vasoconstrictor and increases Aldosterone secretion – salt and H2O retention) and decreases PVR, BP. Also, <b>inhibits bradykinin inactivation</b> to cause vasodilatation and decreased PVR, BP.</p>	<p>Bold to pass</p>
<p>LOA: 2</p>	<p>What are the adverse effects of captopril?</p>	<p><b>Hypotension</b>, 1<sup>st</sup> dose esp. if hypovolaemic, diuretics, NaCl restriction, GI loss <b>ARF</b> esp. with bilateral RAS <b>HyperK+</b> esp. if renal insuff, DM <b>Cough, angioedema</b> (bradykinin, substance P), wheeze Fetal abnormalities (hypotension, anuria, renal failure – 2<sup>nd</sup>/3<sup>rd</sup> trim, increased teratogenesis – 1<sup>st</sup> trim) Altered taste, allergic skin rash, drug fever (10%)</p>	<p>3 of Bold to pass</p>
	<p>What drugs interact with captopril?</p>	<p><b>K+ supplements, K+ sparing diuretics</b> – increase hyperK+ NSAIDs – impair BP reduction (block bradykinin) Other antihypertensives; haemaccel</p>	<p>Bold to pass</p>

2013.2A

<p><b>Pharmacology:</b> Amiodarone Indications, mechanism of action, adverse effects</p>	<p>What are the indications for amiodarone?</p>	<p><b>Treatment of atrial and of ventricular tachyarrhythmias.</b> Used both to revert VT &amp; prevent recurrence. Used in VF/VT cardiac arrest (after 3 shocks &amp; adrenaline).</p>	<p>Bold to pass.</p>
	<p>Describe the mechanism of action of amiodarone.</p>	<p>Has Class I, II, III &amp; IV effects. <b>Prolongs the AP duration (hence QT interval) by K channel blockade.</b></p>	<p>Bold to pass.</p>
	<p>Can you describe the possible adverse effects of amiodarone associated with both its short and long term use?</p>	<p><b>Acute: Bradycardia &amp; heartblock ; Hypotension;</b> Chronic: <b>Pulmonary fibrosis;</b> Abnormal LFTs &amp; hepatitis; Skin deposits -&gt; photodermatitis &amp; grey-blue discoloration in sun-exposed areas; Asymptomatic corneal microdeposits; Optic neuritis (rare); Hypo/hyperthyroidism.</p>	<p>All bold and 1 other. Especially in those with pre-existing S/AVN disease. Due to peripheral vasodilation.</p>

2013.2C

<p><b>Question 2</b> <b>PHARMACOLOGY</b> <b>GTN</b> LOA: 1</p>	<p>1. By what routes can GTN be administered?</p>	<p>1. <b>Sublingual, transdermal, IV, oral, buccal, inhaled</b></p>	<p>Bold 3/4</p>
	<p>2. Why are parenteral routes favoured?</p>	<p>2. To avoid the <b>hepatic first pass</b> effect which significantly decreases bio-availability</p>	<p>bold</p>
<p>Katzung 12<sup>th</sup> ed Chapter 12) MoA, principles of tachyphylaxis</p>	<p>3. What is meant by the term tachyphylaxis as it relates to Glyceryl Trinitrate (<b>GTN</b>)</p>	<p>3. Continuous exposure to nitrates – smooth muscle may develop tolerance. Particularly seen with continuous IV infusion or long acting preparations. (oral, transdermal)</p>	<p>Understand concept</p>
	<p>What is the implication of this for the dosing and administration of GTN</p>	<p>Concept of “drug-free” interval – at least 8h between doses</p>	<p>concept</p>
	<p>What is the theoretical basis for this phenomenon? (bonus)</p>	<p>(a) Diminished release of nitric oxide resulting from reduced bioactivation secondary to depletion of tissue thiol compounds, decreased tissue sulphhydryl groups, increased generation of O2 free radicals , decreased availability of CGRP. (b) Systemic compensation – after &gt; 1 day of therapy salt and water retention reverse favourable hemodynamic change</p>	<p>for better candidates</p>
	<p>4. When should GTN be used with caution?</p>	<p>4. <b>hypotension</b>, those on sildenafil, inferior&amp;posterior MI/RV infarct, Fixed cardiac output (AS, tamponade etc), raised ICP, significant tachy/brady cardia, allergy</p>	<p>Bold +2</p>

### 2013.1.1

<p>Question 2 VERAPAMIL LOA: 1</p>	<p>Describe the effects of verapamil on the heart.</p> <p>What are the indications for verapamil?</p> <p>Name some clinical adverse effects</p>	<p>Binds to <math>\alpha_1</math> receptor L-type Ca channel <b>Blocks Ca influx</b> <b>Reduced contractility</b> CO, O<sub>2</sub> demand <b>Reduced</b> impulse generation/<b>conduction AV node</b> Reduced coronary artery spasm</p> <p><b>Angina; hypertension; atrial arrhythmias</b> migraine</p> <p>Extensions of therapeutic action (exacerbated by <math>\beta</math> blockers) <b>Bradycardia; AV block; CCF; hypotension</b> Other Constipation; peripheral oedema; dizziness; flushing; nausea</p>	<p><b>Bolded</b></p> <p><b>2 bolded</b></p> <p><b>2 bolded</b></p>
--------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------

### 2013.1.2

<p>Question 2 PROPRANOLOL LOA: 1</p>	<p>Describe the pharmacodynamics of propranolol.</p> <p>What are the potential adverse effects?</p>	<p><math>\beta</math> antagonist; competitive; non-selective CV <math>\downarrow</math>BP if high -ve inotrope -ve chronotrope <math>\uparrow</math>PR interval <math>\downarrow</math>renin release Resp bronchospasm Eye <math>\downarrow</math>pressure (<math>\downarrow</math>humour production) Metabolic <math>\downarrow</math>glycogenolysis <math>\uparrow</math>VLDL <math>\downarrow</math>HDL</p> <p>Bradycardia; <math>\uparrow</math>CCF; <math>\uparrow</math>PVD <math>\downarrow</math>hypoglycaemia response Bronchospasm Sedation/depression Abrupt withdrawal effects Exacerbate Ca channel blocker effects</p>	<p>2 CV + 1 other</p> <p>Bradycardia, bronchospasm and 1 other</p>
----------------------------------------------	-----------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------

### 2013.1.3

<p>Question 2 GLYCERYL TRINITRATE (GTN) LOA: 1</p>	<p>How does Glyceryl Trinitrate (GTN) exert its effect on smooth muscle?</p> <p>Describe the Pharmacokinetics of GTN</p> <p><b>Prompt:</b> How is GTN given?</p>	<p>Nitrate <math>\rightarrow</math> <b>Nitric Oxide</b> <math>\rightarrow</math> <math>\uparrow</math>cGMP <math>\rightarrow</math> relaxation <math>\rightarrow</math> <b>vasodilation</b> Also involves Prostaglandin E or prostacyclin</p> <p><b>Low Bioavail</b> (&lt;10-20%) Sublingual, transdermal or IV S/L: onset 1-3min, lasting 10-30min Liver metabolism and excreted by kidney Tachyphylaxis with continuous use</p>	<p><b>Nitric Oxide , cGMP/second messenger, vasodilation</b></p> <p><b>Low Bioavailability</b> <b>Short half-life</b></p>
------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------

### 2012.1.3

<p>Question 5 LOA: 1 <b>DRUGS IN AF</b> <b>SOTALOL</b></p>	<p>List the classes of drugs used for the management of AF in the emergency department</p> <p>Describe the pharmacodynamics of sotalol:</p> <p>List the main side effects</p> <p>What drug interactions with Sotalol prolong the QT? <i>Prompt: What other interactions can occur with sotalol?</i></p>	<p>B-blockers Ca-channel blockers Cardiac glycosides Class 1c antiarrhythmics Class 3 antiarrhythmics</p> <p><b>Non-selective beta blocker, Class II</b> <b>Prolongs plateau phase Class III</b></p> <p>Pro-arrhythmic- Esp <b>prolongation of QT</b> and Torsades CCF Asthma, AV blockade</p> <p><b>Drugs which prolong QT-</b> phenothiazines, Macrolides, eg erythromycin, quinolones antidepressants,- Increased risk of Torsades Drugs which cause hypokalaemia hypomagnesaemia increase risk of Torsades Myocardial depressant drugs- increased LVF Calcium channel blockers, class 1a antiarrhythmics, may increase refractory time and contraction</p>	<p>3 of 5</p> <p>Need class II + III</p> <p>Prolonged QT + 1 other</p> <p>2 examples</p>
------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------

### 2012.2.3

<p>Question 2 adenosine</p> <p>LOA: 1</p>	<p>What are the indications for use of Adenosine?</p> <p>How does it work?</p> <p>How do the specific pharmacokinetic properties of adenosine influence the method of administration?</p>	<p><b>Conversion of paroxysmal SVT to sinus rhythm.</b></p> <p>Activation of inward rectifier K<sup>+</sup> currents and inhibition of calcium currents. Leads to marked hyperpolarisation and suppression of calcium-dependent APs. Effect is direct inhibition of AV nodal conduction and increase in AV node RP. <b>This interrupts re-entry pathway thru AV node.</b></p> <p><b>Very rapid metabolism</b> by adenosine deaminase in red cells and vessels walls = very short elimination t<sub>1/2</sub> (&lt;10s) and duration of action (~30s). Must be given by <b>rapid intravenous bolusing</b>. If initial dose ineffective then subsequent dose should be increased (no accumulation occurs).</p>	<p>Bold to pass</p> <p>AV node conduction interruption</p> <p>Bold to pass</p>
-----------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------

### 2011.1.1

<p><b>Anti-arrhythmics in AF</b></p>	<p>What anti arrhythmic drugs can be used in the management of atrial fibrillation</p> <p>What are the mechanisms of action of amiodarone?</p> <p>Prompt: what are the cellular mechanisms</p> <p>What are some important drug interactions with amiodarone?</p>	<p>Beta-antagonists (class 2); calcium-antagonists (class 4); flecainide (class 1c); amiodarone (class 3); digoxin (unclassified); magnesium</p> <p><b>Blocks Na, K, Ca channels; blocks beta adrenoreceptors;</b> prolongs AV conduction; decreases automaticity; decreases automaticity of purkinje fibres</p> <p>Has actions on both rate and rhythm!</p> <p>warfarin (increased anticoagulant effect by inhibiting metabolism); digoxin ( increases plasma concentration leading to toxicity); increased cardiac effects of other antiarrhythmic agents; phenytoin ( increased plasma concentration)</p>	<p>Pass 3/5</p> <p>Bold</p> <p>At least 2</p>
--------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------

### 2011.1.3

<p><b>Digoxin side effects and toxicity</b></p>	<p>What are the features of digoxin toxicity?</p> <p>What factors might predispose patients towards digoxin toxicity?</p> <p>Prompt: are there any interactions?</p>	<p>G-I: anorexia, nausea, vomiting diarrhoea CNS: visual disturbances, confusion, nightmares, agitation, drowsiness Cardiac: features of bradycardia (progressing AV block, slow AF) and increased automaticity (VEBS and bigeminy, SVT with AV block, VT/VF)</p> <p><b>Electrolyte imbalance</b> Hypokalaemia, hypercalcaemia, hypomagnesaemia</p> <p><b>Organ disease</b> Renal impairment, hypothyroidism,</p> <p><b>Other drugs</b> Amiodarone, calcium channel blockers, potassium depleting drugs</p>	<p>Needs to recognise GI/CNS/Cardiac, as well as examples of bradycardia and inc. automaticity to pass</p> <p>Bold (with at least one example of each) to pass</p>
-------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 2011.1.3

<p><b>Adenosine</b></p>	<p>What are the principal effects of adenosine on cardiac conduction?</p> <p>Describe the pharmacokinetics of adenosine.</p> <p>What are the clinical implications of this pharmacokinetic profile?</p> <p>Name some indications and contraindications to its use.</p>	<p><b>Inhibits AV nodal conduction</b></p> <p><b>Rapidly metabolised.</b> By red cells and endothelial cells <b>Very short elimination half-life</b> (seconds)</p> <p>Therefore must be given by <b>rapid IV bolus</b>. Side effects are short lived. No prolonged action to keep patient out of the arrhythmia. (Proximal IV site as preference).</p> <p>Indication: <b>supraventricular tachycardia</b>; diagnostic Contraindications: AV block, sick sinus, acute asthma, lack of consent</p>	<p>Bold</p> <p>Bold</p> <p>Bold</p> <p>SVT and 1 CI.</p>
-------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------

### 2011.1.3

<p><b>Drugs used in hypertensive emergencies</b></p>	<p>List some drugs used in hypertensive emergencies.</p> <p>Tell us about the pharmacokinetics of Na nitroprusside .</p> <p>What are the potential toxicities of Na nitroprusside?</p>	<p>GTN , nifedipine , diazoxide , hydralazine , nitroprusside , esmolol , labetalol</p> <p>IV administration, <b>onset minutes</b>, peak effect minutes, <b>1/2 life 2 minutes</b> (thiocyanate 3 days), duration of action 1-10 minutes, <b>elimination-RBC's to cyanide, liver to thiocyanate</b>, renally excreted</p> <p><b>Cyanide toxicity</b> - hypotension , metabolic acidosis , pink skin , tachypnoea decreased reflexes , dilated pupils , coma <b>Thiocyanate toxicity</b> - ataxia , blurred vision , headache , nausea , vomiting , tinnitus, SOB, delirium, unconsciousness</p>	<p>At least 3 drugs</p> <p>2/4 Bold</p> <p>Both bolded categories and 1 example of each.</p>
------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------

### 2011.2.2

<p>Question 2: Calcium channel blockers</p>	<p>a) What are the effects of Ca channel blockers on smooth muscle? (Prompt: tissue level)</p> <p>b) By what mechanisms do Ca channel blockers control angina?</p> <p>c) Why is verapamil more efficacious than dihydropyridines in the treatment of arrhythmias?</p>	<p>a) <b>Relax smooth muscle esp vascular smooth muscle</b> Arterioles more sensitive than veins Does effect bronchiolar GIT and uterine</p> <p>b) <b>Decrease myocardial contractility</b> Decrease oxygen demand <b>Decrease afterload by relaxing vascular smooth muscle</b> Verapamil/ diltiazem have a non-specific antiadrenergic effect and decrease heart rate Relieve and prevent coronary artery spasm</p> <p>c) Blockade of L-channels more marked in tissues that fire frequently More marked effects on tissues that depend on Ca channels for activation, SA &amp; AV nodes More marked on tissues with tissues less polarised at rest</p>	<p>Bolded</p> <p>Bolded</p> <p>Supplementary</p>
-------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------

## 2011.2.2

<p>Question 4 Noradrenaline</p>	<p>a) What is the adrenoreceptor selectivity of noradrenaline? (prompt "what receptors does it act on")</p> <p>b) Describe the cardiovascular effects of infused noradrenaline</p>	<p>a) <b>alpha 1 = alpha2; Beta 1 &gt;&gt; Beta 2</b> alpha 1: post-synaptic effector cells, especially smooth muscle alpha 2: presynaptic nerve terminals, platelets, lipocytes, smooth muscle beta 1: post synaptic effector cells, especially heart, lipocytes, brain</p> <p>b) 1. <b>Increases peripheral vascular resistance</b> 2. <b>Increases SBP and DBP</b> 3. Little chronotropy 4. <b>Positive inotropy</b></p>	<p>all 3 bold to pass</p> <p>2 of 3 bold to pass</p>
-------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------

## 2011.2.3

<p>Question 2 Loop Diuretics</p>	<p>a) What are the mechanisms of action of FRUSEMIDE?</p> <p>b) What are the toxic effects of FRUSEMIDE?</p>	<p>a)</p> <ul style="list-style-type: none"> <li>• inhibits NKCC2 = a luminal Na<sup>+</sup>/K<sup>+</sup>/2Cl co-transporter of <b>thick ascending limb of Loop of Henle</b></li> </ul> <p>=&gt; <b>decreased reabsorption of NaCl</b></p> <p>=&gt; diuresis</p> <ul style="list-style-type: none"> <li>• increased prostaglandin synthesis</li> </ul> <p>=&gt; a) inhibition of salt transport in thick ascending limb</p> <p>=&gt; b) increased renal blood flow, decreased pulmonary congestion, decreased LV filling pressures</p> <p>b)</p> <ul style="list-style-type: none"> <li>• <b>decreased K</b> metabolic alkalosis</li> <li>• ototoxicity</li> <li>• hyperuricaemia</li> <li>• hypomagnesaemia</li> <li>• Allergy - rash, eosinophilia, interstitial nephritis</li> <li>• dehydration</li> <li>• hyponatraemia</li> </ul>	<p><b>bold to pass</b></p> <p>4+ to pass - must include <b>decr K</b> &amp; one non-electrolyte</p>
--------------------------------------	--------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------

## 2010.1.1

<p>Question 4: Amiodarone P228-9</p>	<p>1. What are the cardiac effects of amiodarone at a <u>cellular</u> level?</p> <p>2. What are the mechanisms of pharmacokinetic drug interaction with Amiodarone and give two examples.</p>	<p>Prolongs AP duration (by blocking K<sup>+</sup> channels) Blocks inactivated Na channels. The AP prolonging action reinforces this effect. Blocks depolarized cells &gt; normal cells. Mild antisympathetic. noncompetitive inhibitor of beta receptors; Weak adrenergic blocker - slows HR and A-V node conduction. Weak Ca channel blocker. Inhibits abnormal automaticity; slows sinus rate; increases PR interval</p> <p>Inhibits liver cytochrome metabolising enzymes Digoxin, Warfarin levels increase. Cimetidine increases amiod toxicity by decreasing hepatic clearance. Interacts with statins (atorvastatin and simvastatin; instead use pravastatin as not P450). Concentration and effects of Phenytoin, anaesthetics, cyclosporins, theophylline, procainamide, flecainide, quinidine are increased by amiodarone</p>	<p>K block and 1 other</p> <p>Enzyme induction/inhibition + 1 example of either</p>
----------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------

## 2010.1.2

<p>Question 4: Metoprolol P147-55, 169</p>	<p>1. Describe the pharmacokinetics of metoprolol</p> <p><i>What's the bioavailability?</i> <i>Why is this so?</i></p> <p>2. How does metoprolol differ from propranolol in its action at beta receptors?</p> <p>3. How do B Blockers control hypertension?</p>	<p>Oral or IV, Well absorbed Bioavailability 50% due to first-pass effect Large volume of distribution Half-life, 3-4 hours Metabolised in the liver</p> <p>B1 equipotent B2 50-100 fold less potent</p> <p>Not fully understood Negative inotropic and chronotropic effects Slow a-v node conduction Antagonises release of renin caused by sympathetic nervous system</p>	<p>Large Vd + first pass</p> <p>B1 selective</p> <p>Negative inotrope/chronotrope</p>
----------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------

### 2010.1.3

Question 4: Atropine P108-9, 114-6	1. Describe the pharmacokinetics of atropine	Oral or IV (usually), neb, topical; Well absorbed orally Widely distributed (including CNS) Half-life 2 hours Elimination: 60% excreted renally unchanged 40% phase I and phase II metabolism and renally excreted	Wide distribution + short t1/2
	2. At which receptors does atropine act?	Muscarinic (equipotent at M1, M2 and M3) Nicotinic (minimal potency)	Predominant Muscarinic
	3. What are the effects of atropine on heart rate?	Lower doses often an initial bradycardia, (Blocks prejunctional M1 receptors); Tachycardia	Dose dependant

### 2010.2.1

<p>2.</p> <p>a. Describe the mechanism of action of glyceryl trinitrate.</p> <p>b. What are the clinical effects of nitrates</p>	<ul style="list-style-type: none"> <li>• Taken up by <b>vascular smooth muscle</b></li> <li>• Interacts with tissue sulfhydryl groups</li> <li>• Releases free radical <b>nitric oxide</b></li> <li>• Activates cGMP</li> <li>• Dephosphorylates myosin light chains</li> <li>• <b>Reduces intracellular Ca levels</b></li> <li>• Smooth muscle relaxation &amp; <b>vasodilation</b></li> </ul> <ul style="list-style-type: none"> <li>• Low doses – venodilation ⇒ ↓ preload &amp; stroke volume</li> <li>• Higher doses – arterial dilation ⇒ ↓ <b>blood pressure</b></li> <li>⇒ ↓ cardiac output &amp; ↓ <b>myocardial oxygen demand</b></li> <li>+ dilation of coronary arteries/redistribution of perfusion</li> <li>⇒ <b>improved oxygen delivery to myocardium &amp; resolution of ischaemic pain</b></li> </ul> <p><b>[Prompt if needed “What other clinical effects may be seen?”]</b></p> <ul style="list-style-type: none"> <li>• Adverse effects: postural hypotension, tachycardia, dizziness, headache, flushing, blurred vision, dry mouth, rash</li> </ul>	<p>Must state</p> <ul style="list-style-type: none"> <li>• <b>vascular smooth muscle</b></li> <li>• <b>nitric oxide</b></li> <li>• <b>vasodilation</b></li> </ul> <p>Must state</p> <ul style="list-style-type: none"> <li>• <b>↓ BP</b></li> <li>• <b>↓ myocardial oxygen demand</b></li> <li>• 2 listed other effects</li> </ul>
----------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



2010.2.2

<p>2. a. Describe the mechanism of action of ACE inhibitors</p> <p>b. What are the adverse effects of ACE inhibitors</p>	<ul style="list-style-type: none"> <li>• competitive <b>block conversion of angiotensin I to II</b> ⇒             <ul style="list-style-type: none"> <li>○ <b>decreased vascular tone</b> from prevention of vasoconstrictor effects of Ang II (main effect)</li> <li>○ <b>inhibition of aldosterone secretion</b> caused by Ang II leading to reduced Na &amp; H<sub>2</sub>O resorption ⇒ decreased BP</li> </ul> </li> <li>• <b>dizziness, hypotension</b></li> <li>• headaches, weakness</li> <li>• loss of taste, nausea, diarrhoea</li> <li>• rash, fever, joint pain</li> <li>• <b>cough</b></li> <li>• mild hyperkalaemia due to decrease in aldosterone secretion</li> <li>• acute renal failure</li> </ul>	<p>3 in <b>bold</b> to pass</p> <ul style="list-style-type: none"> <li>• hypotension or dizziness</li> <li>• cough</li> <li>• plus 2 others</li> </ul>
<p>c. What are some drug interactions that occur with ACE inhibitors</p>	<ul style="list-style-type: none"> <li>• Diuretics ⇒ hypotension</li> <li>• General anaesthetics ⇒ hypotension</li> <li>• Lithium ⇒ lithium toxicity</li> <li>• NSAIDS ⇒ hyperkalaemia &amp; reduced effects of ACE inhibitor</li> <li>• Potassium sparing diuretics / potassium supplements ⇒ hyperkalaemia</li> </ul>	<p>2 to pass</p>

2010.2.3

<p>2. a. What are the pharmacokinetic properties of frusemide?</p> <p>b. What are the site and mechanism of action of frusemide ?</p>	<ul style="list-style-type: none"> <li>• Rapid absorption after oral admin</li> <li>• Oral bioavailability 50% (range 10 –100%)</li> <li>• Highly protein-bound (&gt;95%)</li> <li>• 50% conjugated in kidney &amp; 50% excreted in urine unchanged (tubular secretion)</li> <li>• Elimination t<sup>1</sup>/<sub>2</sub> 1.5 – 2 hours</li> <li>• Peak effect 30 minutes IV / 1 hour oral</li> <li>• Actively secreted into lumen of nephron from proximal tubule cells via organic-base pump</li> <li>• Inhibits Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> transporter in <b>thick ascending limb of loop of Henle</b> thus <b>preventing resorption of Na<sup>+</sup> &amp; Cl<sup>-</sup></b></li> <li>• Abolishes counter-current concentrating mechanism leading to a dilute urine</li> </ul>	<p>Must list 3 properties</p> <p>Must mention thick ascending limb of loop of Henle and reduced resorption of Na and Cl.</p>
<p>C. What are the adverse effects of the frusemide?</p>	<ul style="list-style-type: none"> <li>• Electrolyte disturbances – <b>hypokalemia, hyponatraemia</b>, hypomagnesaemia, hyperuricaemia</li> <li>• Postural <b>hypotension</b> &amp; dizziness</li> <li>• Increased LDL &amp; triglycerides, decreased HDL</li> <li>• Ototoxicity (high dose IV)</li> <li>• Drug interactions</li> </ul>	<p>Must list</p> <ul style="list-style-type: none"> <li>• Hypokalemia</li> <li>• Hyponatremia</li> <li>• Hypotension or dizziness</li> <li>• 1 other</li> </ul>

### 2009.2.3

Question 4: Calcium Channel Blockers	<ul style="list-style-type: none"> <li>What is the mechanism of action of CCBs?</li> </ul>	<ul style="list-style-type: none"> <li>CCBs bind to receptors on alpha 1, 2, gamma and delta subunits of L-type Ca channel → ↓ frequency of opening of Ca channels in response to depolarisation → ↓ transmembrane Ca current → ↓ Ca influx → <ul style="list-style-type: none"> <li>vascular smooth muscle relaxation</li> <li>↓ contractility in cardiac muscle</li> <li>↓ SA node pacemaker rate</li> <li>↓ AV node conduction velocity</li> </ul> </li> </ul>	Need anti-arrhythmic and smooth muscle effects
	<ul style="list-style-type: none"> <li>What are the toxic effects of CCB's</li> </ul>	<ul style="list-style-type: none"> <li>Cardiovascular: cardiac arrest; bradycardia; AV block; heart failure, hypotension</li> <li>Minor: flushing, dizziness, nausea, constipation, peripheral oedema</li> </ul>	2 cardiovascular

### 2009.1.1

Question 2: Adrenaline	<ol style="list-style-type: none"> <li>What are the effects of adrenaline on the blood vessels in different tissue?</li> <li>What receptors mediate these effects?</li> </ol>	Vascular resistance Cutaneous            α Mucous membranes       α Skeletal muscle       β <sub>2</sub> , α Renal            α, D Splanchnic        α, β Venous tone        α, β	Pass: 3 tissues + receptors
	<ol style="list-style-type: none"> <li>Describe the effects of adrenaline on other organs besides the heart.</li> </ol>	<b>Respiratory</b> Bronchodilation <b>Eyes</b> Pupillary dilation, Intraocular pressure – decreases, also decrease production of aqueous humor) Relaxation of <b>gastric</b> smooth muscle <b>Genitourinary</b> Uterine smooth muscle relaxation, Bladder relaxation, Bladder sphincter contraction, Ejaculation <b>Apocrine</b> sweat glands – palm of hands <b>Salivary</b> glands leading to dry mouth <b>Lipolysis</b> – increased fatty acids and glycerol in circulation <b>Liver</b> – enhanced glycogenolysis <b>Metabolic acidosis</b> Decreased extracellular <b>potassium</b> <b>Leucocytosis</b> <b>Insulin</b> inhibits or stimulates insulin secretion	3 organs

### 2009.1.2

Question 2: Digoxin	<ol style="list-style-type: none"> <li>What are the actions of digoxin on the heart at therapeutic levels?</li> </ol>	Mechanical (Na-K ATPase) Electrical: Direct – alters action potential Indirect (autonomic) - parasympathetic effects predominate Sensitisation of baroreceptors Central vagal stimulation Facilitation of muscarinic transmission	Pass: Mechanical and one other.
	<ol style="list-style-type: none"> <li>Are the parasympathetic effects uniform through-out the heart?</li> </ol>	No Affect atrial and A – V nodal function more than Purkinje or ventricular function	

### 2009.1.3

Question 2 Antihypertensives	<ol style="list-style-type: none"> <li>What are the sites of action of antihypertensive drugs (with examples)?</li> </ol>	Vasomotor centre – clonidine, methyl dopa Sympathetic ganglia - trimethaphan Sympathetic nerve terminals – guanethidine, reserpine <b>β receptors of heart</b> – β blockers <b>Angiotensin receptors of bv</b> – AT II receptor blockers <b>α receptors of bv</b> - prazosin <b>Vascular smooth muscle</b> – hydralazine, SNP, Ca blockers, GTN <b>Kidney tubules</b> - diuretics <b>β cells juxtaglomerular cells</b> – β-blockers <b>ACE</b>	Pass 4 of bold.
---------------------------------	---------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------

### 2008.2.3

Question 5: Flecainide	<ol style="list-style-type: none"> <li>What is flecainide's mechanism of action?</li> </ol>	<b>Na channel blockade</b> (class effect). Predominant action is to inhibit the fast, or sodium, channel which is largely responsible for the rapid upstroke of the myocardial action potential in cardiac conducting tissue <b>Class 1C action</b> - - minimal effect on the Action Potential Duration and dissociates from the Na channel with slow kinetics. (no effect on QT interval) Decrease the rate of rise ( $V_{max}$ , phase 0) of the action potential with little effect on duration.	Na channel block, class 1C
	<ol style="list-style-type: none"> <li>Describe flecainide's pharmacokinetics.  <b>Prompt</b> Usual oral dose            Tambocar trade name</li> </ol>	Well absorbed orally, half life ~ 20 hours, Peak plasma drug levels at ~ 3 hours (range 1-6 hrs), Vd ranges from 5 to 13.4 L/kg (mean 8.7 L/kg), 30% of a single oral dose (range 10 to 50%) is excreted in urine as unchanged drug – remainder by hepatic metabolism. Usual dose 100-200 mg daily	2 things
	<ol style="list-style-type: none"> <li>In which patients is it contraindicated?</li> </ol>	Hypotension, LV dysfunction	Any answer

### 2008.1.1

Angiotensin 2 Blockers	Describe the pharmacodynamics of therapeutic drugs that modulate the effect of angiotensin (Prompt to ACE & receptor blockers) What are the advantages of Angiotensin 2 receptor antagonists over ACE inhibitors ? (Specifically with respect to side effects)	ACE inhibitors – bind ACE reversibly preventing conversion of AI to AII. Inhibitory action on the renin-angiotensin system Stimulating action on the kallikrein-kinin system Angiotensin II inhibitors – competitive antagonists at A II receptor. As AII inhibitors do not result in production of bradykinins, there is a decreased incidence of cough and angioedema. Potentially greater effect as enzymes other than ACE can generate AII (Pass – able to describe actions and basic effects of ACE inhibitors and understanding that AII receptor antagonists and ACE inhibitors have different mechanisms.)	
------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

### 2008.1.1

Atropine	What is the mechanism of action of atropine ?  What are the toxic effects of atropine? (Prompt - due to excessive use or abuse)  What are the therapeutic uses for atropine ?	Antimuscarinic at cholinergic receptors  Tachycardia, flushing, dry skin mucous, mydriasis membranes, ileus, urinary retention, acute angle glaucoma, central anticholinergic syndrome (delirium with visual hallucinations)  Symptomatic bradycardias, especially when vagally mediated. OGP poisoning/ Inocybe Mushroom poisoning, drying of secretions. Adjunct to reversal of non depolarising muscle relaxants and suxamethonium administration in young infants. Antispasmodic, mydriatic.  (Pass – antimuscarinic, at least 2 indications and 3 adverse effects involving 3 different body systems)	
----------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

### 2008.1.2

Loop Diuretics	How does frusemide exert its action ?  What are the adverse effects of frusemide? (Are any other organ systems effected ?)	Selective inhibition of NaCl reabsorption in the thick ascending loop of Henle Hypokalemic Metabolic Alkalosis Ototoxicity Hyperuricemia Hypomagnesemia . Allergy Skin rash Eosinophilia Interstitial nephritis Hyponatremia  (Pass – Na & loop of Henle, 4 adverse effects incl hypokalaemia & one non electrolyte)	
----------------	----------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

### 2008.1.3

Nitrates	What is the cellular mechanism of action of GTN ?  How does GTN relieve angina pain ?  Outline the pharmacokinetics of sublingual GTN	Denitration by glutathione S-transferase. Free nitrite ions released and form NO. NO activates guanylyl cyclase leading to increased cGMP and dephosphorylation of myosin and smooth muscle relaxation (precise mechanism unknown)  Venodilation leads to reduced venous return, reduce ventricular volume and reduced heart wall tension. This reduces myocardial O2 requirement.  Oral bioavailability is low due to extensive first pass hepatic metabolism by high capacity organic nitrate reductase. Rapid and efficient absorption by sublingual or intranasal routes but rapid elimination (t1/2 2-8 mins) and duration of action (15-30 mins) due to high capacity hepatic metabolism. Denitrated metabolites conjugated to glucuronide and excreted in urine.	Production of NO leading to smooth muscle relaxation to pass  Need to know that venodilation and reduced venous is major factor reducing myocardial o2 requirement.  Poor oral bioavailability due extensive first pass metabolism and effective alternative routes of administration to pass
----------	---------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Older

1.2 GTN- Pharmacodyna mics of	<p>How does GTN exert its effect on smooth muscle?</p> <p>What are the clinical effects of GTN ?</p>	<p>Nitrite → NO → ↑cGMP → relaxation. Prostaglandins also involved</p> <p>Venodilation → reduced venous return → reduced LVEDV → reduced LV wall tension → reduced myocardial oxygen consumption (→ reduced cardiac output in normal people, possibly increased in pathological conditions where pretreatment preload is abnormally high)</p> <p><b>Prompts if needed:</b></p> <ul style="list-style-type: none"> <li>- "How does GTN relieve angina?"</li> <li>- "How does the effect of GTN on cardiac output differ between normal and disease states?"</li> </ul> <p>Other: Arterial dilation → throbbing headache (relatively ineffective on resistance vessels)</p> <p>Other smooth muscle relaxation (eg amyl nitrite + enhanced erection) less important Decreased platelet aggregation, but no apparent beneficial therapeutic effect in this regard Methaemoglobinaemia from nitrite but not from GTN</p>	/2
2.2 Beta Blockers	<p>What are the pharmacokinetic features of Beta Blockers?</p> <p>What are the effects of beta blockers?</p> <p>What are the effects of beta blocker in overdose?</p>	<p>Well absorbed, low bioavailability, large volume of distribution. Most are metabolized in liver <b>(must get 2)</b></p> <p>Decrease in hypertension, negative chronotrope and negative ionotrope, atrioventricular block, increased survival after AMI, Bronchospasm, decreased IO pressure <b>(must get 2)</b></p> <p>Hypotension, bradycardia, cardiogenic shock, bronchospasm, seizures (cerebrotoxic), NB Propranolol causes arrhythmias through Type 1 antiarrhythmic effects (Na channel block) <b>(must get 3)</b></p>	/2
3.2 Atropine	<p>What is the mechanism of action of atropine?</p> <p>Give examples of organ effects</p> <p>What are the features of atropine poisoning</p>	<p>Reversible block of <b>cholinergic muscarinic receptors</b></p> <p>CNS: decrease tremor and rigidity in Parkinson's disease Eye:– mydriasis and cycloplegia Cardiovascular: SA ( and AV) node; blocks vagal slowing → rel tachycardia and incr conduction ( shorten PR ), block coronary vasodilation Respiratory: blocks M receptors on smooth muscle and secretions Gastrointestinal: Blocks motility and secretions Genitourinary Relaxes smooth muscle in ureters and bladder wall ( spasm) and slows voiding ( retention) Skin: decreases sweating <b>(must get 3)</b></p> <p>Agitation and delirium Raised temp Blurred vision / mydriasis Dry mouth / flushed skin Tachycardia <b>(must get 4)</b></p>	/4
2.4 Osmotic diuretics ( including mannitol)	<p>How are osmotic diuretics handled by the kidney?</p> <p>What are the clinical uses of Mannitol?</p> <p>What are the toxic effects of Mannitol?</p>	<p>Freely filtered by glomeruli. Not reabsorbed, causes water retention in the freely permeable sections of the nephron = proximal tubule and descending loop of Henle</p> <p>IV dose 0.5-1-2 g/kg for raised intracranial pressure. Rarely for intraocular pressure and diuresis in haemolysis or rhabdomyolysis</p> <p>Extracellular volume expansion, Hyponatraemia <b>(must get 1)</b></p>	/2
Digoxin	<p>Describe the molecular action of digoxin?</p> <p>What are the cardiac effects?</p> <p><i>PROMPT for autonomic effects: What are the autonomic effects of digoxin?</i></p>	<p><b>Na<sup>+</sup>/K<sup>+</sup> ATPase ("sodium pump") inhibition</b></p> <p>Mechanical: ↑<b>contractility</b> due to ↑intensity of interaction of actin and myosin filaments due to ↑<b>free calcium</b> during systole</p> <p>Electrical: (i) Direct: <b>Shortening of action potential</b> and ∴ shortened atrial and ventricular refractoriness At toxic levels, resting membrane potential reduced, then as toxicity progresses depolarizing afterpotentials (ii) Autonomic- at lower doses <b>parasymp effects</b> predominate At toxic levels sympathetic outflow increased</p>	<p>Binds to α subunit which has different isoforms ∴ differing affinities for digoxin in various tissues Low concentrations occasionally stimulate the enzyme</p> <p>(i) ↑intracellular Na<sup>+</sup> and ∴ (ii) relative ↓expulsion of Ca<sup>+</sup> by NaCa exchanger (Fig 13-1) Duration of contractile response neither shortened (as in case of βblockers) nor lengthened (as in case of methylxanthines)</p> <p>Follows early brief prolongation of AP Probably due to ↑K<sup>+</sup> conductance</p> <p>Overloaded intracell Ca<sup>+</sup> stores</p> <p>Atropine –blockable effects: sensitization of baroreceptors, central vagal stim, facilitation of muscarinic transmission (mainly atria and AV node where rich cholinergic innerv'n) Sensitizes myocardium and exaggerates all</p>

	<p>What are the non cardiac manifestations of digoxin toxicity?</p> <p>?enough time for this question. Describe the pharmacokinetics of digoxin?</p>	<p>-all excitable tissue including smooth muscle and CNS GIT nausea, vomiting, diarrhoea, anorexia CNS disorientation, hallucinations, visual disturbances, agitation and convulsions Gynaecomastia <b>1 GIT and 1 CNS example (prompt allowed)</b> Hyperkalaemia</p> <p>Well absorbed orally</p> <p>Moderate Volume of Distribution (6.3 L/kg)</p> <p>Not extensively metabolized, 2/3 excreted unchanged by kidneys</p>	<p>toxic effects Relative low sensitivity of non-cardiac tissue ?due to differing enzyme isoforms</p> <p>Nausea and vomiting a combination of direct and central effects</p> <p>10% population with enteric bacteria that reduce oral bioavailability 20-40% plasma protein bound</p>
--	----------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

amiodarone	<p>Describe the mechanism of action of amiodarone?</p> <p>What are the clinical uses of amiodarone?</p> <p>Describe the potential adverse effects of amiodarone?</p>	<p><b>Potassium Channel Blocker (Class III)</b> Prolongs RP, APD <b>Na channel blockade</b> Weak Ca &amp; adrenergic blocking</p> <p><b>Atrial &amp; ventricular arrhythmias</b></p> <p>Cardiac: Bradycardia, Heart block, hypotension, negative inotropy Pulmonary fibrosis, Abnormal LFTs &amp; hepatitis, Skin deposits Corneal microdeposits Hypo/hyperthyroidism. <b>2 cardiac, 2 extracardiac</b></p>	<p>Prolongs the effective refractory period by prolonging the action potential duration Blocks inactivated sodium channels (Class I) Weak adrenergic (Class II) and calcium channel (Class IV) blocking actions Vasodilator</p> <p>Maintaining normal sinus rhythm in AF Prevention of Recurrent VT</p> <p>photodermatitis and a gray-blue skin discoloration -blocks the peripheral conversion of thyroxine (T<sub>4</sub>) to triiodothyronine (T<sub>3</sub>)</p>
------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2. Ca Channel Blockers	<p>At a cellular level describe the action of calcium channel blockers.</p> <p>What are the differences in pharmacodynamics between dihydropyridines and other Ca channel blockers?</p> <p>How are these differing pharmacodynamics reflected in their side effect profile?</p>	<p>Bind at intracellular L type calcium channel</p> <p>Dihydropyridines are vascular smooth muscle selective Verapamil / Diltiazem greater effect on cardiac/conducting tissue</p> <p>Dihydropyridines cause flushing, headache &amp; tachycardia Verapamil causes bradycardia Both can cause hypotension</p>	
------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

2. Thiazide Diuretics	<p>1. How do thiazides exert their diuretic action</p> <p>2. What are the adverse effects of thiazides?</p> <p>(3/6 FOR PASS)</p>	<p>Inhibition of NaCl reabsorption in the distal convoluted tubule</p> <p>1. Hypokalaemic metabolic alkalosis and hyperuricaemia 2. Impaired carbohydrate tolerance 3. Hyperlipidaemia 4. Hyponatraemia 5. Allergic reactions (sulphonamides) 6. Weakness, fatigue, paraesthesia (like carbonic anhydrase inhibitors)</p>	
-----------------------	-----------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

2. Class 1 Anti-arrhythmics: mechanism of action	<p>How do you classify Class I anti-arrhythmic drugs Give an example of each (1 EACH CLASS FOR PASS) What are their different effects on the action potential</p>	<p>a, b, c</p> <p>1a: prolong, 1b: nil, 1c: minimal</p>	
--------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------	--

Beta blockers (carvedilol)	<p>Describe the pharmacodynamics of propranolol.</p> <p>How does carvedilol differ from propranolol?</p>	<ul style="list-style-type: none"> <li>• <b>Non-selective action on Beta receptors,</b></li> <li>• <b>Membrane stabilizing action,</b></li> <li>• <b>Antagonizes renin release from symp ns.</b></li> <li>• <b>Competitive, pure antagonist.</b></li> </ul> <p>(2 out of 4 + 1 of the rest in notes).</p> <p>Carvedilol has no local anaesthetic action. <b>Causes Alpha 1 adrenoceptor block, but effect on Beta receptor &gt; Alpha receptor.</b> Stereoselective metabolism of its 2 isomers occurs (with polymorphism influenced Cytochrome P450 2D6 affecting R isomer metabolism). <b>(1 out of 3)</b></p>	<p>Inhibits sympathetic ns stimulation of lipolysis, Inhibits liver glycogenolysis, Reduces aqueous humour production, Increases VLDL, Decreases HDL. Blocks B2 receptor in bronchial smooth muscle increasing airway resistance.</p>
----------------------------	----------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Lignocaine	<p>What are the pharmacodynamic effects of lignocaine on the heart?</p> <p>What features distinguish lignocaine from other Class 1 Antiarrhythmics?</p> <p>What are the clinical uses of lignocaine?</p>	<ul style="list-style-type: none"> <li>• <b>Selectively blocks the fast Na channels of the depolarised cells, increasing their refractory period.</b></li> <li>• Decreases pacemaker activity.</li> <li>• May cause hypotension by depressing myocardial contractility in those with heart failure.</li> </ul> <p><b>(bold + 1)</b></p> <ul style="list-style-type: none"> <li>• <b>Does not prolong the duration of the AP.</b></li> <li>• Dissociates from the channel with rapid kinetics</li> <li>• Has no effect on normal cells.</li> </ul> <p><b>(1 of 3)</b></p> <ul style="list-style-type: none"> <li>• <b>Type 1B Antiarrhythmic</b></li> <li>• <b>Local Anaesthetic</b></li> <li>• Post herpetic neuralgia</li> </ul> <p><b>(2 of 3)</b></p>	Type 1B antiarrhythmic. Affects cells with the longest APs, such as purkinje and ventricular cells as opposed to the atrial cells.
------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------

Nitrates	<p>What is the mechanism of action of glyceryl trinitrate in smooth muscle ?</p> <p>How do nitrates relieve angina ?</p>	<p>NO release, cGMP increases</p> <p>Preload reduction decreases myocardial work</p>	
----------	--------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------	--

Loop diuretics	<p>Describe the mechanism of action of Frusemide</p> <p>What effects do they have on renal handling of Ca and Mg ?</p>	<p>Na/K/ 2Cl pump, thick ascending limb Henle</p> <p>Excretes calcium</p>	
----------------	------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------	--

Digoxin toxicity	<p>What are the clinical manifestations of digoxin toxicity ?</p> <p>What is the specific antidote for digoxin toxicity ?</p> <p>What are the indications for the use of digibind ?</p>	<p>At least one example of each of CNS, GIT and cardiac</p> <p>Digi whats it</p> <p>Cardiac arrhythmias, hyperkalaemia</p>	
------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------	--

Beta receptor antagonists	<p>Describe the pharmacokinetics of propranolol</p> <p>Describe the cardiovascular effects of beta blockers</p>	<p>High 1<sup>st</sup> pass, liver metabolism, lipid solubility high</p> <p>B blockade with variable selectivity, negative inotropic and chronotropic</p>	
---------------------------	-----------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------	--

Lignocaine	<p>Describe the mechanism of action of lignocaine on the heart</p> <p>Describe the adverse effects of lignocaine</p>	<p>Na channel blockade</p> <p>Stepwise CNS effects</p> <p>Cardiovascular Na blockade</p>	
------------	----------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------	--

B receptor agonists	1. Regarding B agonists, by what cellular mechanism do they exert their effects?	Bind to specific receptor. <b>G-protein activation.</b> Stimulate adenylyl cyclase. <b>Increased cyclic AMP.</b> <b>Increased free intracellular Ca.</b> Activate protein kinase.	<b>Bold items required to pass.</b>
	2. Compare the cardiovascular of adrenaline and dobutamine.	<b>Adrenaline has B1, B2 and alpha effects.</b> <b>Increased inotrope and chronotrope.</b> <b>Peripheral vasoconstriction in most vascular beds.</b> Vasodilatation in skeletal muscle beds (B2). May reduce TSVR. <b>Dobutamine is a selective B1 agonist.</b> <b>Increases cardiac output</b> with less reflex tachycardia as it has fewer B2 effects. Comes as racemic mixture of +ve and -ve isomers. One isomer has B agonist and alpha antagonist effects; the other has alpha agonist effects.	<b>Bold items required to pass.</b>

FIRST QUESTION	What is the mechanism of action of captopril	
	<b>Inhibit converting enzyme</b> peptidyl dipeptidase which a. <b>hydrolyzes AI to AII – get decreases peripheral vasc. resistance, CO and HR same</b> b. <b>inactivates bradykinin – therefore get vasodilation, decr. Peripheral vascular resistance, decr. BP</b>	
SECOND QUESTION	What are the clinical uses of captopril	
	a. CHF, after MI (better preservation of LVF – reduce post MI remodeling) b. Diabetic nephropathy – diminish proteinuria, stabilize renal function – improved intrarenal hemodynamics c. Hypertension	Know  Know
THIRD QUESTION	What are the adverse effects of captopril	
	Hypotension after 1 <sup>st</sup> dose if hypovolemic, diuretics, NaCl restriction, GI loss ARF (bilateral renal a. stenosis) Hyperkalemia – if renal insufficiency, DM Dry cough, angioedema (bradykinin, substance P) Fetal problems if 2 <sup>nd</sup> , 3 <sup>rd</sup> trimester Neutropenia, proteinuria from high dose captopril Minor – change taste, skin rash, drug fever	Know

FIRST QUESTION	What is the mechanism of action of adenosine?	
	It acts at adenosine receptors Enhances K conductance and inhibition of cAMP induced Ca influx – get marked hyperpolarization and suppression of C-dependent A.P. Bolus dose, inhibits AV nodal conduction, increases AV nodal refractory period, lesser effects on SA nodal function PROMPT: Where in the heart does it act?	
SECOND QUESTION	How is it administered	
	Fast IV bolus via large vein	
THIRD QUESTION	What are the indications for the use of adenosine	
	Supraventricular tachycardia Unmasks Aflutter/Afib	
FOURTH QUESTION	What are the adverse effects?	
	Flushing in 20% patients SOB, chest burning in 10% High grade AV block short lived/ Afib H/ache, hypotension, nausea, paresthesias	Dyspnea High grade AV block